Merck & Co., Inc. (NYSE:MRK) is a global healthcare company known for its innovative medicines, vaccines, and animal health products. The company faces competition from other pharmaceutical giants like Pfizer and Johnson & Johnson. On March 12, 2026, Mohit Bansal from Wells Fargo set a price target of $150 for MRK, suggesting a potential increase of 29.07% from its then-current price of $116.22, as highlighted by StreetInsider.
Despite this optimistic outlook, Merck is grappling with challenges, particularly with its Gardasil vaccine. In 2025, Gardasil sales dropped by 39% year over year, totaling $5.2 billion. This decline is largely due to weak demand in China, where an economic slowdown has led to high inventory levels at Merck's partner, Zhifei. Consequently, Merck has paused Gardasil shipments to China.
The situation is further complicated by reduced demand for Gardasil in Japan and declines in other vaccines. Merck's management does not expect Gardasil sales to recover in 2026, which could continue to pressure the company's revenue. This ongoing challenge is a significant factor for investors to consider when evaluating MRK's potential growth.
Currently, MRK's stock price is $115.48, reflecting a slight decrease of 0.63% from the previous day. The stock has traded between $114.30 and $115.82 today, with a market capitalization of approximately $285.5 billion. Over the past year, MRK has seen a high of $125.14 and a low of $73.31, indicating some volatility in its stock performance.
Today's trading volume for MRK is 687,521 shares, which provides insight into investor interest and market activity. As Merck navigates its challenges with Gardasil and other vaccines, investors will be closely watching how these factors impact the company's financial health and stock performance.
